Unwinding of PHE is a top priority for CMS

The latest stories trending on MedCity News.

Editor's Pick

Top Story CMS Administrator: Telehealth Flexibilities Greatly Expanded Access, But Up To Congress To Extend During an interview at the AHIP Medicare, Medicaid, Duals and Commercial Markets Forum held Tuesday in Washington, D.C., CMS Administrator Chiquita Brooks-LaSure discussed CMS' key focus areas for 2023. This includes the end of the public health emergency, health equity and prescription drug costs.

Featured News

Pfizer's Seagen Acquisition Brings It Full Circle in a Hot Area of Cancer Drug R&D Pfizer is no stranger to antibody drug conjugate cancer therapies, but it hasn't been commercially successful with them. The pharma giant's agreement to acquire Seagen for $43 billion will thrust it to the forefront of the ADC drug class, which has become a hot space for research and regulatory activity in recent years. The Future of Heart Health – Continuous Heart Monitoring When it comes to heart health, time is of the essence. ECGs are considered the most reliable tools, but only if they are continuous and long-term in nature. Continuous Heart Rhythm Monitoring is simply the only solution for prevention and/or management for the number one global health issue. How to Tap Into the Partner Ecosystem in Healthcare to Speed Up Disruption Our challenges in the health space are too daunting for any single organization to tackle alone. We need to draw from both the strengths of the incumbents and the start-ups that have emerged in recent years, whether the challenge is in navigating care, simplifying care delivery, or fostering stronger patient engagement. US Sues Rite Aid for Ignoring Glaring 'Red Flags' in Opioid Prescriptions The Department of Justice filed a lawsuit against Rite Aid, accusing the pharmacy chain of filling hundreds of thousands of opioid prescriptions that had "obvious, and often multiple, red flags." The DOJ claimed that Rite Aid violated the Controlled Substances Act by filling unlawful prescriptions for addictive drugs, as well as the False Claims Act when the chain sought reimbursement from federal healthcare programs for these prescriptions. Novo Nordisk Follows Eli Lilly's Lead, Lowering Insulin Prices up to 75% Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant's insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.

Resources

Introducing MedCity Moves, a New Podcast on Healthcare's Corporate Ladder In the first episode, aside from providing an overview of healthcare's latest leadership and layoff news, Senior Reporter Katie Adams interviews Dr. Taha Kass-Hout, who recently became GE Healthcare's chief technology officer, about healthcare's corporate ladder. Listen Now

MedCity News • 611 Broadway • New York, NY unsubscribe